ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy
Abstract Introduction The recently published randomized multicenter open label ISAR REACT 5 trial showed that prasugrel was superior to ticagrelor with respect to the composite primary end point of death, myocardial infarction, or stroke at one year after randomization in patients with acute coronar...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2020-11, Vol.41 (Supplement_2) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_2 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 41 |
| creator | Bongiovanni, D Mayer, K Schreiner, N Karschin, V Wustrow, I Gosetti, R Schuepke, S Schunkert, H Laugwitz, K.L Kastrati, A Bernlochner, I |
| description | Abstract
Introduction
The recently published randomized multicenter open label ISAR REACT 5 trial showed that prasugrel was superior to ticagrelor with respect to the composite primary end point of death, myocardial infarction, or stroke at one year after randomization in patients with acute coronary syndrome with planned invasive evaluation. The reasons for this finding are speculative.
Purpose
The aim of this prespecified platelet aggregation substudy was to assess platelet aggregation induced by adenosine-diphosphate (ADP) in patients who received prasugrel or ticagrelor treatment and underwent PCI.
Methods
We assessed all patients who underwent PCI and who had valid ADP-induced platelet aggregation values at hospital admission and at 2–24 hours after administration of prasugrel or ticagrelor loading dose followed by maintenance dose. ADP-induced platelet aggregation values were measured using the Mulitplate Analyzer®. Patients were recruited in the German Heart Center, Munich, Germany or in Klinikum rechts der Isar, Munich, Germany, Technical University of Munich.
Results
A total of 608 patients were analyzed. Patients in the prasugrel group were slightly but significantly older than patients in the ticagrelor group (66,5 years versus 64,6 years, P=0,048). The remaining baseline characteristics did not significantly differ between the two treatment groups. ADP-induced platelet aggregation (median [IQR]) at baseline did not differ between prasgurel- and ticagrelor treated patients (809 [556; 1057] AU x min versus 797 [534–1095] AU x min. At 2–24 hours after study drug administration ADP-induced platelet aggregation was significantly lower in patients who had received prasugrel in comparison to ticagrelor (105 [57–176] AU x min versus 138 [77–207] AU x min (Figure 1).
Conclusion
ADP-induced platelet aggregation was significantly lower in patients who received prasugrel in comparison to patients who received ticagrelor, which could have influenced patients' outcome in the ISAR-REACT 5 trial.
Figure 1
Funding Acknowledgement
Type of funding source: None |
| doi_str_mv | 10.1093/ehjci/ehaa946.1721 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ehjci_ehaa946_1721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/ehaa946.1721</oup_id><sourcerecordid>10.1093/ehjci/ehaa946.1721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1301-89bdc1ad3ee23f9f1bcb08ae1e7033df5516d1f3313a6e616435e59a54dfd6ae3</originalsourceid><addsrcrecordid>eNqNkEFOwzAQRS0EEqVwAVa-QIodx26yjEqBSpVApUjsIscet6nSOLIdoR6JW-LSLlmwmfmL__9oHkL3lEwoKdgDbHeqiVPKIhMTOk3pBRpRnqZJITJ-iUaEFjwRIv-8Rjfe7wghuaBihL7Lx7ek6fSgQOO-lQFaCFhuNg42MjS2w02H-6igCx5_NWGLpRoCYGWd7aQ7YH_otLN7wMFBjOuTqXfSD7Gkxdbh0Ch51NZN8Ar80MYqa3DYAl68lyu8mpezNeZ_3_dD7cOgD7foysjWw915j9HH03w9e0mWr8-LWblMFGWEJnlRa0WlZgApM4WhtapJLoHClDCmDedUaGoYo0wKiAwyxoEXkmfaaCGBjVF66lXOeu_AVL1r9vHTipLqCLv6hV2dYVdH2DGUnEJ26P_j_wHaUoh1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Bongiovanni, D ; Mayer, K ; Schreiner, N ; Karschin, V ; Wustrow, I ; Gosetti, R ; Schuepke, S ; Schunkert, H ; Laugwitz, K.L ; Kastrati, A ; Bernlochner, I</creator><creatorcontrib>Bongiovanni, D ; Mayer, K ; Schreiner, N ; Karschin, V ; Wustrow, I ; Gosetti, R ; Schuepke, S ; Schunkert, H ; Laugwitz, K.L ; Kastrati, A ; Bernlochner, I</creatorcontrib><description>Abstract
Introduction
The recently published randomized multicenter open label ISAR REACT 5 trial showed that prasugrel was superior to ticagrelor with respect to the composite primary end point of death, myocardial infarction, or stroke at one year after randomization in patients with acute coronary syndrome with planned invasive evaluation. The reasons for this finding are speculative.
Purpose
The aim of this prespecified platelet aggregation substudy was to assess platelet aggregation induced by adenosine-diphosphate (ADP) in patients who received prasugrel or ticagrelor treatment and underwent PCI.
Methods
We assessed all patients who underwent PCI and who had valid ADP-induced platelet aggregation values at hospital admission and at 2–24 hours after administration of prasugrel or ticagrelor loading dose followed by maintenance dose. ADP-induced platelet aggregation values were measured using the Mulitplate Analyzer®. Patients were recruited in the German Heart Center, Munich, Germany or in Klinikum rechts der Isar, Munich, Germany, Technical University of Munich.
Results
A total of 608 patients were analyzed. Patients in the prasugrel group were slightly but significantly older than patients in the ticagrelor group (66,5 years versus 64,6 years, P=0,048). The remaining baseline characteristics did not significantly differ between the two treatment groups. ADP-induced platelet aggregation (median [IQR]) at baseline did not differ between prasgurel- and ticagrelor treated patients (809 [556; 1057] AU x min versus 797 [534–1095] AU x min. At 2–24 hours after study drug administration ADP-induced platelet aggregation was significantly lower in patients who had received prasugrel in comparison to ticagrelor (105 [57–176] AU x min versus 138 [77–207] AU x min (Figure 1).
Conclusion
ADP-induced platelet aggregation was significantly lower in patients who received prasugrel in comparison to patients who received ticagrelor, which could have influenced patients' outcome in the ISAR-REACT 5 trial.
Figure 1
Funding Acknowledgement
Type of funding source: None</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/ehjci/ehaa946.1721</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2020-11, Vol.41 (Supplement_2)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1301-89bdc1ad3ee23f9f1bcb08ae1e7033df5516d1f3313a6e616435e59a54dfd6ae3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Bongiovanni, D</creatorcontrib><creatorcontrib>Mayer, K</creatorcontrib><creatorcontrib>Schreiner, N</creatorcontrib><creatorcontrib>Karschin, V</creatorcontrib><creatorcontrib>Wustrow, I</creatorcontrib><creatorcontrib>Gosetti, R</creatorcontrib><creatorcontrib>Schuepke, S</creatorcontrib><creatorcontrib>Schunkert, H</creatorcontrib><creatorcontrib>Laugwitz, K.L</creatorcontrib><creatorcontrib>Kastrati, A</creatorcontrib><creatorcontrib>Bernlochner, I</creatorcontrib><title>ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy</title><title>European heart journal</title><description>Abstract
Introduction
The recently published randomized multicenter open label ISAR REACT 5 trial showed that prasugrel was superior to ticagrelor with respect to the composite primary end point of death, myocardial infarction, or stroke at one year after randomization in patients with acute coronary syndrome with planned invasive evaluation. The reasons for this finding are speculative.
Purpose
The aim of this prespecified platelet aggregation substudy was to assess platelet aggregation induced by adenosine-diphosphate (ADP) in patients who received prasugrel or ticagrelor treatment and underwent PCI.
Methods
We assessed all patients who underwent PCI and who had valid ADP-induced platelet aggregation values at hospital admission and at 2–24 hours after administration of prasugrel or ticagrelor loading dose followed by maintenance dose. ADP-induced platelet aggregation values were measured using the Mulitplate Analyzer®. Patients were recruited in the German Heart Center, Munich, Germany or in Klinikum rechts der Isar, Munich, Germany, Technical University of Munich.
Results
A total of 608 patients were analyzed. Patients in the prasugrel group were slightly but significantly older than patients in the ticagrelor group (66,5 years versus 64,6 years, P=0,048). The remaining baseline characteristics did not significantly differ between the two treatment groups. ADP-induced platelet aggregation (median [IQR]) at baseline did not differ between prasgurel- and ticagrelor treated patients (809 [556; 1057] AU x min versus 797 [534–1095] AU x min. At 2–24 hours after study drug administration ADP-induced platelet aggregation was significantly lower in patients who had received prasugrel in comparison to ticagrelor (105 [57–176] AU x min versus 138 [77–207] AU x min (Figure 1).
Conclusion
ADP-induced platelet aggregation was significantly lower in patients who received prasugrel in comparison to patients who received ticagrelor, which could have influenced patients' outcome in the ISAR-REACT 5 trial.
Figure 1
Funding Acknowledgement
Type of funding source: None</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkEFOwzAQRS0EEqVwAVa-QIodx26yjEqBSpVApUjsIscet6nSOLIdoR6JW-LSLlmwmfmL__9oHkL3lEwoKdgDbHeqiVPKIhMTOk3pBRpRnqZJITJ-iUaEFjwRIv-8Rjfe7wghuaBihL7Lx7ek6fSgQOO-lQFaCFhuNg42MjS2w02H-6igCx5_NWGLpRoCYGWd7aQ7YH_otLN7wMFBjOuTqXfSD7Gkxdbh0Ch51NZN8Ar80MYqa3DYAl68lyu8mpezNeZ_3_dD7cOgD7foysjWw915j9HH03w9e0mWr8-LWblMFGWEJnlRa0WlZgApM4WhtapJLoHClDCmDedUaGoYo0wKiAwyxoEXkmfaaCGBjVF66lXOeu_AVL1r9vHTipLqCLv6hV2dYVdH2DGUnEJ26P_j_wHaUoh1</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Bongiovanni, D</creator><creator>Mayer, K</creator><creator>Schreiner, N</creator><creator>Karschin, V</creator><creator>Wustrow, I</creator><creator>Gosetti, R</creator><creator>Schuepke, S</creator><creator>Schunkert, H</creator><creator>Laugwitz, K.L</creator><creator>Kastrati, A</creator><creator>Bernlochner, I</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy</title><author>Bongiovanni, D ; Mayer, K ; Schreiner, N ; Karschin, V ; Wustrow, I ; Gosetti, R ; Schuepke, S ; Schunkert, H ; Laugwitz, K.L ; Kastrati, A ; Bernlochner, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1301-89bdc1ad3ee23f9f1bcb08ae1e7033df5516d1f3313a6e616435e59a54dfd6ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bongiovanni, D</creatorcontrib><creatorcontrib>Mayer, K</creatorcontrib><creatorcontrib>Schreiner, N</creatorcontrib><creatorcontrib>Karschin, V</creatorcontrib><creatorcontrib>Wustrow, I</creatorcontrib><creatorcontrib>Gosetti, R</creatorcontrib><creatorcontrib>Schuepke, S</creatorcontrib><creatorcontrib>Schunkert, H</creatorcontrib><creatorcontrib>Laugwitz, K.L</creatorcontrib><creatorcontrib>Kastrati, A</creatorcontrib><creatorcontrib>Bernlochner, I</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bongiovanni, D</au><au>Mayer, K</au><au>Schreiner, N</au><au>Karschin, V</au><au>Wustrow, I</au><au>Gosetti, R</au><au>Schuepke, S</au><au>Schunkert, H</au><au>Laugwitz, K.L</au><au>Kastrati, A</au><au>Bernlochner, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy</atitle><jtitle>European heart journal</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>41</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
Introduction
The recently published randomized multicenter open label ISAR REACT 5 trial showed that prasugrel was superior to ticagrelor with respect to the composite primary end point of death, myocardial infarction, or stroke at one year after randomization in patients with acute coronary syndrome with planned invasive evaluation. The reasons for this finding are speculative.
Purpose
The aim of this prespecified platelet aggregation substudy was to assess platelet aggregation induced by adenosine-diphosphate (ADP) in patients who received prasugrel or ticagrelor treatment and underwent PCI.
Methods
We assessed all patients who underwent PCI and who had valid ADP-induced platelet aggregation values at hospital admission and at 2–24 hours after administration of prasugrel or ticagrelor loading dose followed by maintenance dose. ADP-induced platelet aggregation values were measured using the Mulitplate Analyzer®. Patients were recruited in the German Heart Center, Munich, Germany or in Klinikum rechts der Isar, Munich, Germany, Technical University of Munich.
Results
A total of 608 patients were analyzed. Patients in the prasugrel group were slightly but significantly older than patients in the ticagrelor group (66,5 years versus 64,6 years, P=0,048). The remaining baseline characteristics did not significantly differ between the two treatment groups. ADP-induced platelet aggregation (median [IQR]) at baseline did not differ between prasgurel- and ticagrelor treated patients (809 [556; 1057] AU x min versus 797 [534–1095] AU x min. At 2–24 hours after study drug administration ADP-induced platelet aggregation was significantly lower in patients who had received prasugrel in comparison to ticagrelor (105 [57–176] AU x min versus 138 [77–207] AU x min (Figure 1).
Conclusion
ADP-induced platelet aggregation was significantly lower in patients who received prasugrel in comparison to patients who received ticagrelor, which could have influenced patients' outcome in the ISAR-REACT 5 trial.
Figure 1
Funding Acknowledgement
Type of funding source: None</abstract><pub>Oxford University Press</pub><doi>10.1093/ehjci/ehaa946.1721</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2020-11, Vol.41 (Supplement_2) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_ehjci_ehaa946_1721 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| title | ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A10%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ADP-induced%20platelet%20aggregation%20in%20patients%20with%20acute%20coronary%20syndrome%20treated%20with%20prasugrel%20or%20ticagrelor.%20Results%20of%20the%20ISAR%20REACT%205%20platelet%20aggregation%20substudy&rft.jtitle=European%20heart%20journal&rft.au=Bongiovanni,%20D&rft.date=2020-11-01&rft.volume=41&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/ehjci/ehaa946.1721&rft_dat=%3Coup_cross%3E10.1093/ehjci/ehaa946.1721%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ehjci/ehaa946.1721&rfr_iscdi=true |